These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 28148716

  • 1. A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer.
    Pathak RK, Wen R, Kolishetti N, Dhar S.
    Mol Cancer Ther; 2017 Apr; 16(4):625-636. PubMed ID: 28148716
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of nanoparticle delivered cisplatin in beagles.
    Feldhaeusser B, Platt SR, Marrache S, Kolishetti N, Pathak RK, Montgomery DJ, Reno LR, Howerth E, Dhar S.
    Nanoscale; 2015 Sep 07; 7(33):13822-30. PubMed ID: 26234400
    [Abstract] [Full Text] [Related]

  • 3. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 4. Platin-C containing nanoparticles: a recipe for the delivery of curcumin-cisplatin combination chemotherapeutics to mitochondria.
    Banik B, Ashokan A, Choi JH, Surnar B, Dhar S.
    Dalton Trans; 2023 Mar 21; 52(12):3575-3585. PubMed ID: 36723189
    [Abstract] [Full Text] [Related]

  • 5. Detouring of cisplatin to access mitochondrial genome for overcoming resistance.
    Marrache S, Pathak RK, Dhar S.
    Proc Natl Acad Sci U S A; 2014 Jul 22; 111(29):10444-9. PubMed ID: 25002500
    [Abstract] [Full Text] [Related]

  • 6. Targeted combinational therapy inducing mitochondrial dysfunction.
    Shin WS, Park SK, Verwilst P, Koo S, Lee JH, Chi SG, Kim JS.
    Chem Commun (Camb); 2017 Jan 19; 53(7):1281-1284. PubMed ID: 28067351
    [Abstract] [Full Text] [Related]

  • 7. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.
    Pathak RK, Dhar S.
    Chemistry; 2016 Feb 24; 22(9):3029-36. PubMed ID: 26807548
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.
    Elias MG, Aputen AD, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR.
    Int J Mol Sci; 2024 Jul 28; 25(15):. PubMed ID: 39125821
    [Abstract] [Full Text] [Related]

  • 9. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 10. Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer.
    Lu H, Tong W, Jiang M, Liu H, Meng C, Wang K, Mu X.
    ACS Nano; 2024 Aug 13; 18(32):21156-21170. PubMed ID: 39088743
    [Abstract] [Full Text] [Related]

  • 11. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 12. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X, Fang L, Chen F, Gou S.
    Eur J Med Chem; 2017 Sep 08; 137():167-175. PubMed ID: 28586717
    [Abstract] [Full Text] [Related]

  • 13. Achieving traceless ablation of solid tumors without recurrence by mild photothermal-chemotherapy of triple stimuli-responsive polymer-drug conjugate nanoparticles.
    Du C, Ding Y, Qian J, Zhang R, Dong CM.
    J Mater Chem B; 2019 Jan 21; 7(3):415-432. PubMed ID: 32254729
    [Abstract] [Full Text] [Related]

  • 14. A mitochondria-targeting heptamethine cyanine-chlorambucil formulated polymeric nanoparticle to potentiate native tumor chemotherapeutic efficacy.
    Liu J, Zhang J, Zhang Y, Wei W, Zhan M, Zhang Z, Liu B, Hu X, He W.
    Biomater Sci; 2024 May 14; 12(10):2614-2625. PubMed ID: 38591255
    [Abstract] [Full Text] [Related]

  • 15. Structural modifications of mitochondria-targeted chlorambucil alter cell death mechanism but preserve MDR evasion.
    Jean SR, Pereira MP, Kelley SO.
    Mol Pharm; 2014 Aug 04; 11(8):2675-82. PubMed ID: 24922525
    [Abstract] [Full Text] [Related]

  • 16. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
    Kang X, Wang Y, Chen Z, Wu Y, Chen H, Yang X, Yu C.
    Chem Commun (Camb); 2020 Sep 28; 56(76):11271-11274. PubMed ID: 32830841
    [Abstract] [Full Text] [Related]

  • 17. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S.
    Bioorg Chem; 2020 Jun 28; 99():103768. PubMed ID: 32217375
    [Abstract] [Full Text] [Related]

  • 18. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H.
    J Med Chem; 2024 Apr 25; 67(8):6218-6237. PubMed ID: 38573870
    [Abstract] [Full Text] [Related]

  • 19. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 20. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
    Li C, Li T, Huang L, Yang M, Zhu G.
    Chem Asian J; 2019 May 02; 14(9):1570-1576. PubMed ID: 30843348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.